CN113288892B - 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用 - Google Patents

聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用 Download PDF

Info

Publication number
CN113288892B
CN113288892B CN202110218734.7A CN202110218734A CN113288892B CN 113288892 B CN113288892 B CN 113288892B CN 202110218734 A CN202110218734 A CN 202110218734A CN 113288892 B CN113288892 B CN 113288892B
Authority
CN
China
Prior art keywords
indazol
aminocarbonyl
phenyl
trifluoroacetate
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110218734.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113288892A (zh
Inventor
沈孝坤
肖亮
栗增
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukang Biotechnology Shanghai Co ltd
Original Assignee
Fukang Shanghai Health Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fukang Shanghai Health Technology Co ltd filed Critical Fukang Shanghai Health Technology Co ltd
Publication of CN113288892A publication Critical patent/CN113288892A/zh
Application granted granted Critical
Publication of CN113288892B publication Critical patent/CN113288892B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202110218734.7A 2020-02-24 2021-02-24 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用 Active CN113288892B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020101117554 2020-02-24
CN202010111755 2020-02-24

Publications (2)

Publication Number Publication Date
CN113288892A CN113288892A (zh) 2021-08-24
CN113288892B true CN113288892B (zh) 2024-04-26

Family

ID=77319076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110218734.7A Active CN113288892B (zh) 2020-02-24 2021-02-24 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用

Country Status (6)

Country Link
US (1) US20240016775A1 (enExample)
EP (1) EP4112049A4 (enExample)
JP (1) JP7881489B2 (enExample)
CN (1) CN113288892B (enExample)
CA (1) CA3169303A1 (enExample)
WO (1) WO2021169984A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300229A (en) * 2020-07-31 2023-03-01 Univ Alberta Using beta-catenin/WNT pathway inhibitors to block replication of SARS-COV-2 and other pathogenic viruses
CN115554303B (zh) * 2021-09-18 2024-07-09 上海科技大学 一种三环类化合物、其制备方法及其应用
CN116836173B (zh) * 2023-08-31 2023-12-12 甫康（上海）健康科技有限责任公司 亚胺酰基酰肼类化合物、含其的组合物和其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017128036A1 (zh) * 2016-01-26 2017-08-03 中国医学科学院药物研究所 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
WO2018044136A1 (ko) * 2016-09-05 2018-03-08 충남대학교 산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
CN110194762A (zh) * 2018-02-27 2019-09-03 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
JP2003528073A (ja) * 2000-03-20 2003-09-24 エヌ・ジーン リサーチ ラボラトリーズ インコーポレイテッド プロペンカルボン酸アミドキシム誘導体、その製法、及びこの誘導体を含有する医薬組成物
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
US20090275619A1 (en) 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
GB0700432D0 (en) 2007-01-10 2007-02-21 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
CN103242273B (zh) 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
JP6768693B2 (ja) * 2015-03-30 2020-10-14 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を投与する方法
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
TWI791519B (zh) * 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
CN109134409B (zh) 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN110241198A (zh) * 2019-05-30 2019-09-17 成都吉诺迈尔生物科技有限公司 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法
CN110527744A (zh) * 2019-05-30 2019-12-03 四川大学华西第二医院 一组与同源重组修复缺陷相关的基因组特征性突变指纹的鉴定方法
US11648211B2 (en) * 2019-09-23 2023-05-16 Northeastern University Nanoencapsulated combination drug formulations
WO2021249996A1 (en) * 2020-06-08 2021-12-16 Oncology Venture ApS Compositions comprising 2x-121 and methods for treating coronavirus infection
IL300229A (en) * 2020-07-31 2023-03-01 Univ Alberta Using beta-catenin/WNT pathway inhibitors to block replication of SARS-COV-2 and other pathogenic viruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017128036A1 (zh) * 2016-01-26 2017-08-03 中国医学科学院药物研究所 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途
WO2018044136A1 (ko) * 2016-09-05 2018-03-08 충남대학교 산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
CN110194762A (zh) * 2018-02-27 2019-09-03 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
新型冠状病毒的生物学特征及其药物研发策略;郁文亮;李家璜;华子春;;药物生物技术(01);第1-7页 *
新型冠状病毒肺炎潜在治疗药物――洛匹那韦/利托那韦;苏铮;樊士勇;;临床药物治疗杂志(02);第56-61页 *

Also Published As

Publication number Publication date
JP2023514794A (ja) 2023-04-10
WO2021169984A1 (zh) 2021-09-02
CN113288892A (zh) 2021-08-24
JP7881489B2 (ja) 2026-06-29
US20240016775A1 (en) 2024-01-18
EP4112049A4 (en) 2024-07-24
CA3169303A1 (en) 2021-09-02
EP4112049A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
JP2019163303A (ja) Ｈｉｖを治療するためのトール様受容体の調節因子
EP3900717B1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
EP4112049A1 (en) Anti-coronavirus application of poly adp ribose polymerase inhibitor
KR20230044446A (ko) 급성 호흡기 장애의 치료 방법
JP2023550638A (ja) ウイルス感染症の処置に使用するための、ｖｓｐ３４阻害剤としてのモルホリノ誘導体
US20210379058A1 (en) Arylamide Compounds For Treatment And Prevention Of Viral Infections
JP2023522689A (ja) ＣｏＶ－２２９Ｅ又はＣｏＶ－ＯＣ４３コロナウイルス感染症の治療において使用される４－（３－（ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－５－イル）ピペラジン
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
CN117510409B (zh) 广谱抗病毒中药单体蝙蝠葛苏林碱、及其药物组合物和应用
CN119587548A (zh) 吩嗪-1-羧酸或其可药用盐在制备抑制非洲猪瘟病毒药物中的用途
JP7293225B2 (ja) 組合せ製品を用いるｒｓｖの処置
CN115350190A (zh) 一种小檗胺在制备治疗非洲猪瘟的制剂中的应用
CN114728006A (zh) 治疗冠状病毒感染的方法
US20250177392A1 (en) Broad spectrum inhibitors of cytomegalovirus
CN120983440B (zh) 雷替曲塞在制备用于治疗由腺病毒感染引起的疾病的药物中的用途
AU2017210921B2 (en) Composition and combined medication method for treating enterovirus infection
CN114652727B (zh) 一种wye-125132在制备用于抗腺病毒感染的药物中的用途
US20240165096A1 (en) Anti Viral Therapy
Rybachuk Antiviral chemotherapeutic agents against equine herpesvirus type 1: the mechanism of antiviral effects of porphyrin derivatives
WO2018213220A1 (en) Ozonides for treating or preventing virus infections
CN100464748C (zh) 消旋去甲胡桐素a制备抗爱滋病毒类药物的应用
WO2026081738A1 (zh) PI3Kα突变选择性抑制剂的用途
CN115192599A (zh) 一种加米霉素在制备治疗非洲猪瘟的制剂中的应用
CN117510408A (zh) 抗病毒中药单体蝙蝠葛碱、及其药物组合物和应用
CN118078816A (zh) 谷美替尼在制备促进髓鞘形成和再生的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 201318 No. 1-28, Lane 588, Tianxiong Road, Pudong New Area, Shanghai

Patentee after: Fukang Biotechnology (Shanghai) Co.,Ltd.

Country or region after: China

Address before: 201318 No. 1-28, Lane 588, Tianxiong Road, Pudong New Area, Shanghai

Patentee before: Fukang (Shanghai) Health Technology Co.,Ltd.

Country or region before: China